News

Dyadic Announces an Important Multi-Year Research and Development Arrangement to Further Advance Its Proprietary C1 Technology

JUPITER, Fla., July 10, 2017 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), announced today that it has entered into a comprehensive series of research and development agreements, including a potential commercialization agreement, with Biotechnology Development for Industry (“BDI Holdings”), a Spanish biotech company, and its subsidiaries – VLP The Vaccines Company, S.L.U. (“VLPbio”), and Biotechnology Developments for Industry in Pharmaceuticals, S.L.U. (“BDI Pharma”) (collectively “BDI”). Dyadic expects to leverage the BDI team’s know-how in the development of next generation vaccines and drugs. Additionally, Dyadic will utilize BDI’s previous C1 industrial fermentation scale-up and commercialization experience with yeast and filamentous fungi processes to further advance Dyadic’s proprietary C1 technology for biopharmaceutical product development and production.

MORE “Dyadic Announces an Important Multi-Year Research and Development Arrangement to Further Advance Its Proprietary C1 Technology”

Scripps Florida Scientists Awarded $2 Million to Develop ‘Industrial Level’ Screening for Treatments of Autism-Related Intellectual Disability

A team of scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded nearly $2 million from the National Institute of Mental Health of the National Institutes of Health to develop an ‘industrial level’ high throughput screening platform that could lead to new treatments for a number of childhood brain disorders.

MORE “Scripps Florida Scientists Awarded $2 Million to Develop ‘Industrial Level’ Screening for Treatments of Autism-Related Intellectual Disability”

New Tool to Identify and Control Neurons

Since scientists began studying the brain, they have asked whether the biology they observed can really be tied to external behaviors. Researchers are building a substantial understanding of the biophysical, molecular, and cellular interactions of neurons, but directly relating those interactions to outward behaviors is an ongoing challenge in the field. “The biophysical properties of neurons are pretty well known,” said Hyungbae Kwon, Ph.D., Research Group Leader at the Max Planck Florida Institute for Neuroscience (MPFI). “What we don’t know well is how these connections and communications trigger our behavior.”

MORE “New Tool to Identify and Control Neurons”

MODERNIZING MEDICINE ANNOUNCES AGREEMENT WITH COVERMYMEDS FOR ELECTRONIC PRIOR AUTHORIZATION

CoverMyMeds, a leader in electronic prior authorization (ePA) solutions, and Modernizing Medicine, the specialty-specific health IT leader, today announced an agreement to bring electronic prior authorization (ePA) functionality to the over 7,500 providers using EMA™, the award winning electronic health record (EHR) system in Modernizing Medicine’s suite of services.

MORE “MODERNIZING MEDICINE ANNOUNCES AGREEMENT WITH COVERMYMEDS FOR ELECTRONIC PRIOR AUTHORIZATION”